WealthOne’s Acadia Pharmaceuticals ACAD Stock Holding History

WealthOne’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,523	Closed	-$25K	–	81
2018 Q4	$25K	Buy	+1,523	New	+$29.6K	0.02%	251

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

WealthOne's ACAD Position: Q1 2019 in Review

WealthOne sold out of Acadia Pharmaceuticals (ACAD) in Q1 2019, closing a stake of 1,523 shares — an estimated $25K sold.

WealthOne first reported a position in ACAD in Q4 2018 and held it in 1 quarter. The position peaked at $25K in Q4 2018. 199 funds tracked by Wall St. Rank hold ACAD as of Q1 2019.

WealthOne reported no remaining Acadia Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
WealthOne sold 1,523 Acadia Pharmaceuticals shares in Q1 2019, an estimated $25K.
WealthOne first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 1 quarter.
WealthOne's Acadia Pharmaceuticals position peaked at $25K in Q4 2018.
199 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2019.

Based on WealthOne's 13F filing for Q1 2019, filed 16 May 2019.